Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 14 Issue 3, September 2020

Volume 14 Issue 3

In this issue...

• Exploring new options for immuno-oncology cell therapies

• Can antibodies combat the coronavirus crisis?

• A snapshot of the CNS diseases market

• Medtech dealmaking trends: a review

3d illustration of a cloud of antibodies. Sebastian Kaulitzki / Alamy Stock Photo.

Can antibodies combat the coronavirus crisis?

    Feature

  • News Feature |

    Partnerships are playing an important role in the pursuit of coronavirus-specific antibodies for diagnostics and therapies for COVID‑19.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    Biotech company APO-T is developing bispecific T cell engagers (BiTEs) that facilitate the attraction of immune effector cells exclusively to cancer sites by targeting cancer cell antigens known as melanoma-associated antigen A (MAGE-A) proteins.

    • APO-T
  • Advertisement Feature |

    GEMoaB’s three proprietary technology platforms have produced a deep pipeline of immunotherapy assets, three of which are currently being investigated in clinical studies, providing the basis for future growth.

    • GEMoaB Monoclonals GmbH
  • Advertisement Feature |

    3T Biosciences has developed an immune response-guided approach for identifying pharmacologically active T cell receptors and their targets in solid tumors. With a pipeline of therapeutics targeting novel tumor antigens, 3T is seeking partners to advance these programs.

    • 3T Biosciences
  • Advertisement Feature |

    IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg-derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever.

    • IGY Life Sciences
  • Advertisement Feature |

    RubrYc Therapeutics has established an antibody discovery engine for the development of epitope-targeted biotherapeutics. Through machine learning, the platform helps reveal natural subdominant and alternative epitopes to target for optimized bio-superior design and as access points to traditionally ‘undruggable’ proteins.

    • RubrYc Therapeutics
  • Advertisement Feature |

    Targeting oncology and autoimmune diseases, Byondis takes its pipeline of development programs to clinical proof-of-concept and then seeks partnerships for later-stage clinical development and commercialization.

    • Byondis B.V.
  • Advertisement Feature |

    Accelerating the drug discovery and development process, Bioelectronica has developed Hypercell, a digital biochemistry integrated single-cell identification and sorting system offering superior output.

    • Bioelectronica
  • Advertisement Feature |

    Sorrento Therapeutics, Inc. is developing a pipeline of fully human immunotherapies selected from its proprietary G-MAB library. Backed by a platform covering discovery, advanced clinical development, manufacturing and a proven track record of commercialization, it seeks to deliver life-changing therapies.

    • Sorrento Therapeutics

Exploring new options for immuno-oncology cell therapies

    Feature

  • News Feature |

    Optimization of CAR-T cell technology and application of other immune cell types such as NK cells are tackling the efficacy, cost and logistical challenges of cell therapies for cancer.

    • Nick Taylor
  • Profiles

  • Advertisement Feature |

    Life-threatening respiratory diseases remain a key therapeutic area of focus for multinational company Zambon. The company has two phase 3 development programs underway for the treatment of bronchiolitis obliterans syndrome (BOS) and non-cystic fibrosis bronchiectasis (NCFB).

    • Zambon SpA
  • Advertisement Feature |

    Owkin is building a federated research ecosystem that is fueling collaborative research around the world while preserving patient privacy and data security.

    • Owkin
  • Advertisement Feature |

    Using its MicroRx platform, 4D pharma is pioneering the development of an emerging class of therapeutics known as live biotherapeutic products to treat a range of indications from cancer and respiratory disease to neurodegeneration.

    • 4D Pharma PLC
  • Advertisement Feature |

    Genome engineering company Synthego pioneers agile genome ‘writing’ with a high-throughput CRISPR-based platform to provide innovative solutions for next-generation therapeutics.

    • Synthego
  • Advertisement Feature |

    By reprogramming the tumor microenvironment Kineta is developing an anti-VISTA immuno-oncology therapy for the treatment of a variety of cancers, including gastric, ovarian, lung and pancreatic cancers.

    • Kineta, Inc.
  • Advertisement Feature |

    ExosomeDx harnesses biological information from exosomes for biomarker discovery and diagnostic development. The company’s pipeline of products includes the ExoDx Prostate test, the first exosome-based liquid biopsy on the market, and various discovery platforms to help solve biopharma’s biomarker-related needs.

    • Exosome Diagnostics
  • Advertisement Feature |

    Karma Oncology combines an agile and adaptable business model with expertise in oncology clinical trials to provide bespoke contract clinical research services for biotechnology companies globally.

    • Karma Oncology
  • Advertisement Feature |

    Combining the precision of antibody targeting with α-amanitin, a novel payload, Heidelberg Pharma has developed a powerful therapeutic platform, with the potential to treat a broad range of cancers.

    • Heidelberg Pharma
  • Advertisement Feature |

    Semi-virtual SELMA Diagnostics is harnessing its SELMA technology to identify changes in circulating DNA taken from blood samples to create diagnostic tests for early cancer detection, diagnosis and treatment.

    • Selma Diagnostics
  • Advertisement Feature |

    Cancer Genetics, Inc., a global leader in technology-driven drug discovery and preclinical services, delivers custom solutions for biotech and pharma companies worldwide developing advanced therapies in precision medicine.

    • Cancer Genetics Inc.
  • Advertisement Feature |

    Rakuten Medical, a clinical-stage privately funded biotechnology company, is developing first-in-class targeted cancer therapies based on Illuminox, a new platform with the potential to treat many types of solid tumor, one of the leading causes of death globally.

    • Rakuten Medical

A snapshot of the CNS diseases market

    Feature

  • Profiles

  • Advertisement Feature |

    Vect-Horus’ versatile drug targeting technology uses receptor-mediated transport to deliver drugs or imaging agents to the brain and cancer tissues.

    • Vect-Horus
  • Advertisement Feature |

    GTX Medical is developing innovative neuromodulation therapies to reverse paralysis and improve functional recovery in individuals living with spinal cord injury.

    • GTX Medical
  • Advertisement Feature |

    InVivo Therapeutics is developing a resorbable biomaterial scaffold, the investigational Neuro-Spinal Scaffold,to treat patients with spinal cord injury (SCI). The Neuro-Spinal Scaffold is in clinical trials for acute SCI, and InVivo is also searching for synergistic pipeline expansion opportunities.

    • InVivo Therapeutics
  • Advertisement Feature |

    DTx Pharma’s next-generation, fatty acid ligand-conjugated oligonucleotides enable efficient delivery of RNA-based therapeutics to cells and tissues throughout the body. With three disease franchises—ocular, neuromuscular and central nervous system (CNS), DTx is seeking partners to realize the potential of its platform.

    • DTx Pharma
  • Advertisement Feature |

    Employing its deep understanding of G-protein coupled receptors (GPCRs) the Beacon Discovery team has delivered more than 20 compounds into clinical development over the past two decades, and is now working with partners to unlock the therapeutic value of challenging receptors in this class.

    • Beacon Discovery

Medtech dealmaking trends: a review

    Feature

  • News Feature |

    Last year saw an uptick in medtech mergers and acquisitions values, whereas financing declined. This year is bringing new opportunities and challenges for the field as it responds to the demands of the coronavirus.

    • Maureen Riordan
    • Amanda Micklus
  • Profiles

  • Advertisement Feature |

    Privately held Creatv MicroTech has developed LifeTracDx tests to detect cancer at the earliest stages, and for providing diagnoses to guide cancer treatments, thereby saving and improving lives.

    • Creatv MicroTech
  • Advertisement Feature |

    ENPICOM’s ImmunoGenomiX (IGX) Platform offers state-of-the-art immunomics data analysis, management and visualization for academic researchers, drug developers, and related service providers.

    • ENPICOM

Search

Quick links